[go: up one dir, main page]

FI944442A0 - 3-O-deasyloitua monofosforyylilipidiä A sisältäviä maksatulehdusrokotteita - Google Patents

3-O-deasyloitua monofosforyylilipidiä A sisältäviä maksatulehdusrokotteita

Info

Publication number
FI944442A0
FI944442A0 FI944442A FI944442A FI944442A0 FI 944442 A0 FI944442 A0 FI 944442A0 FI 944442 A FI944442 A FI 944442A FI 944442 A FI944442 A FI 944442A FI 944442 A0 FI944442 A0 FI 944442A0
Authority
FI
Finland
Prior art keywords
monophosphoryl lipid
vaccines containing
deacylated monophosphoryl
hepatitis vaccines
hepatitis
Prior art date
Application number
FI944442A
Other languages
English (en)
Swedish (sv)
Other versions
FI110843B (fi
FI944442L (fi
Inventor
Nathalie Marie- Garcon-Johnson
Pierre Hauser
Clothilde Thiriart
Pierre Voet
Original Assignee
Smithkline Beecham Biolog
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27450853&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=FI944442(A0) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from GB929206788A external-priority patent/GB9206788D0/en
Priority claimed from GB929206797A external-priority patent/GB9206797D0/en
Priority claimed from GB929206789A external-priority patent/GB9206789D0/en
Priority claimed from GB929206786A external-priority patent/GB9206786D0/en
Application filed by Smithkline Beecham Biolog filed Critical Smithkline Beecham Biolog
Publication of FI944442L publication Critical patent/FI944442L/fi
Publication of FI944442A0 publication Critical patent/FI944442A0/fi
Application granted granted Critical
Publication of FI110843B publication Critical patent/FI110843B/fi

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/39Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/12Viral antigens
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/12Viral antigens
    • A61K39/29Hepatitis virus
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/12Viral antigens
    • A61K39/29Hepatitis virus
    • A61K39/292Serum hepatitis virus, hepatitis B virus, e.g. Australia antigen
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/12Viral antigens
    • A61K39/295Polyvalent viral antigens; Mixtures of viral and bacterial antigens
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/51Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525Virus
    • A61K2039/5252Virus inactivated (killed)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/555Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505Inorganic adjuvants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/555Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511Organic adjuvants
    • A61K2039/55572Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/70Multivalent vaccine
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2730/00Reverse transcribing DNA viruses
    • C12N2730/00011Details
    • C12N2730/10011Hepadnaviridae
    • C12N2730/10111Orthohepadnavirus, e.g. hepatitis B virus
    • C12N2730/10134Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011Details
    • C12N2770/32011Picornaviridae
    • C12N2770/32411Hepatovirus, i.e. hepatitis A virus
    • C12N2770/32434Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Mycology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Communicable Diseases (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
FI944442A 1992-03-27 1994-09-26 Menetelmä 3-O-deasyloitua monofosforyylilipidiä A sisältävän hepatiittirokotteen valmistamiseksi FI110843B (fi)

Applications Claiming Priority (10)

Application Number Priority Date Filing Date Title
GB929206788A GB9206788D0 (en) 1992-03-27 1992-03-27 Vaccine
GB9206797 1992-03-27
GB9206789 1992-03-27
GB9206788 1992-03-27
GB929206797A GB9206797D0 (en) 1992-03-27 1992-03-27 Vaccine
GB929206789A GB9206789D0 (en) 1992-03-27 1992-03-27 Vaccine
GB929206786A GB9206786D0 (en) 1992-03-27 1992-03-27 Vaccine
GB9206786 1992-03-27
PCT/EP1993/000712 WO1993019780A1 (en) 1992-03-27 1993-03-24 Hepatitis vaccines containing 3-o-deacylated monophoshoryl lipid a
EP9300712 1993-03-24

Publications (3)

Publication Number Publication Date
FI944442L FI944442L (fi) 1994-09-26
FI944442A0 true FI944442A0 (fi) 1994-09-26
FI110843B FI110843B (fi) 2003-04-15

Family

ID=27450853

Family Applications (1)

Application Number Title Priority Date Filing Date
FI944442A FI110843B (fi) 1992-03-27 1994-09-26 Menetelmä 3-O-deasyloitua monofosforyylilipidiä A sisältävän hepatiittirokotteen valmistamiseksi

Country Status (28)

Country Link
EP (1) EP0633784B2 (fi)
JP (1) JP3470719B2 (fi)
KR (1) KR100270134B1 (fi)
CN (1) CN1072963C (fi)
AP (1) AP570A (fi)
AT (1) ATE146678T1 (fi)
AU (4) AU3751693A (fi)
CA (1) CA2132833C (fi)
CZ (1) CZ283424B6 (fi)
DE (1) DE69306940T3 (fi)
DK (1) DK0633784T4 (fi)
ES (1) ES2098029T5 (fi)
FI (1) FI110843B (fi)
GR (1) GR3022174T3 (fi)
HK (1) HK1003218A1 (fi)
HU (1) HU221253B1 (fi)
IL (1) IL105161A (fi)
MA (1) MA22842A1 (fi)
MY (1) MY111880A (fi)
NO (1) NO309458B1 (fi)
NZ (1) NZ249868A (fi)
RU (1) RU2121849C1 (fi)
SA (1) SA93130573B1 (fi)
SG (1) SG48375A1 (fi)
SI (1) SI9300149B (fi)
SK (1) SK280160B6 (fi)
UA (1) UA44688C2 (fi)
WO (1) WO1993019780A1 (fi)

Families Citing this family (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9105992D0 (en) * 1991-03-21 1991-05-08 Smithkline Beecham Biolog Vaccine
DK0812593T4 (da) * 1993-03-23 2008-05-13 Smithkline Beecham Biolog Vaccinepræparater indeholdende 3-O-deacyleret monophosphoryllipid-A
US6488934B1 (en) 1995-02-25 2002-12-03 Smithkline Beecham Biologicals S.A. Hepatitis B vaccine
GB9503863D0 (en) * 1995-02-25 1995-04-19 Smithkline Beecham Biolog Vaccine compositions
GB9513261D0 (en) * 1995-06-29 1995-09-06 Smithkline Beecham Biolog Vaccines
PL343429A1 (en) * 1998-03-09 2001-08-13 Smithkline Beecham Biolog Combined vaccine compositions
US6306404B1 (en) 1998-07-14 2001-10-23 American Cyanamid Company Adjuvant and vaccine compositions containing monophosphoryl lipid A
GB9822714D0 (en) * 1998-10-16 1998-12-09 Smithkline Beecham Sa Vaccines
KR100629028B1 (ko) 1998-10-16 2006-09-26 글락소스미스클라인 바이오로지칼즈 에스.에이. 애쥬번트 시스템 및 백신
FI108150B (fi) 1999-02-15 2001-11-30 Sulzer Pumpen Ag Menetelmä ja laitteisto massan käsittelemiseksi
US6635261B2 (en) 1999-07-13 2003-10-21 Wyeth Holdings Corporation Adjuvant and vaccine compositions containing monophosphoryl lipid A
GB9921147D0 (en) * 1999-09-07 1999-11-10 Smithkline Beecham Biolog Novel composition
WO2006032475A2 (en) 2004-09-22 2006-03-30 Glaxosmithkline Biologicals S.A. Staphylococcal immunogenic compositions
US20090081253A1 (en) 2005-03-23 2009-03-26 Glaxosmithkline Biologicals S.A. Composition
DK1951299T3 (da) 2005-11-04 2012-04-02 Novartis Vaccines & Diagnostic Influenzavacciner indeholdende kombinationer af partikelformige adjuvanser og immunforstærkere
CA2628206A1 (en) 2005-11-04 2007-05-10 Novartis Vaccines And Diagnostics S.R.L. Influenza vaccine with reduced amount of oil-in-water emulsion as adjuvant
JP2009514839A (ja) 2005-11-04 2009-04-09 ノバルティス ヴァクシンズ アンド ダイアグノスティクス エスアールエル サイトカイン誘導剤を含むアジュバントインフルエンザワクチン
US10842867B2 (en) 2005-11-04 2020-11-24 Seqirus UK Limited Adjuvanted vaccines with non-virion antigens prepared from influenza viruses grown in cell culture
TR201900418T4 (tr) 2005-12-22 2019-02-21 Glaxosmithkline Biologicals Sa Pnömokok polisakkarit konjugat aşısı.
GB0607088D0 (en) 2006-04-07 2006-05-17 Glaxosmithkline Biolog Sa Vaccine
KR20080089663A (ko) 2006-01-27 2008-10-07 노바티스 백신즈 앤드 다이아그노스틱스 게엠베하 운트 콤파니 카게 적혈구응집소 및 기질 단백질을 함유한 인플루엔자 백신
EP2357184B1 (en) 2006-03-23 2015-02-25 Novartis AG Imidazoquinoxaline compounds as immunomodulators
JP2009534303A (ja) 2006-03-24 2009-09-24 ノバルティス ヴァクシンズ アンド ダイアグノスティクス ゲーエムベーハー アンド カンパニー カーゲー 冷蔵しないインフルエンザワクチンの保存
US20100021503A1 (en) 2006-03-30 2010-01-28 Glaxosmithkline Biologicals S.A. Immunogenic composition
WO2009030978A2 (en) 2006-06-09 2009-03-12 Novartis Ag Conformers of bacterial adhesins
MX2009000660A (es) 2006-07-17 2009-04-08 Glaxosmithkline Biolog Sa Vacuna de influenza.
GB0614460D0 (en) 2006-07-20 2006-08-30 Novartis Ag Vaccines
EP3456348B1 (en) 2006-09-11 2025-03-26 Seqirus UK Limited Making influenza virus vaccines without using eggs
US20110045022A1 (en) 2006-12-06 2011-02-24 Theodore Tsai Vaccines including antigen from four strains of influenza virus
US9452209B2 (en) 2007-04-20 2016-09-27 Glaxosmithkline Biologicals Sa Influenza vaccine
KR101579947B1 (ko) 2007-06-26 2015-12-28 글락소스미스클라인 바이오로지칼즈 에스.에이. 스트렙토코쿠스 뉴모니애 캡슐 다당류 컨쥬게이트를 포함하는 백신
DK2185191T3 (da) 2007-06-27 2012-12-03 Novartis Ag Influenzavacciner med lavt indhold af tilsætningsstoffer
GB0810305D0 (en) 2008-06-05 2008-07-09 Novartis Ag Influenza vaccination
GB0818453D0 (en) 2008-10-08 2008-11-12 Novartis Ag Fermentation processes for cultivating streptococci and purification processes for obtaining cps therefrom
NZ586439A (en) 2007-12-24 2012-10-26 Novartis Ag Method for peforming an immunodiffusion assay (SRID) for influenza hemagglutinin antigen based on desorbing the antigen from the aluminium adjuvant salt
EP2403507B1 (en) 2009-03-05 2018-02-21 McCloskey, Jenny Colleen Treatment of infection
AR077757A1 (es) 2009-07-15 2011-09-21 Novartis Ag Composiciones de proteinas de fusion del virus sincicial respiratorio (rsv) y metodos para su preparacion
GB0913681D0 (en) 2009-08-05 2009-09-16 Glaxosmithkline Biolog Sa Immunogenic composition
GB0913680D0 (en) 2009-08-05 2009-09-16 Glaxosmithkline Biolog Sa Immunogenic composition
NZ611176A (en) 2010-12-02 2015-07-31 Bionor Immuno As Peptide scaffold design
BR112013017488A2 (pt) 2011-01-06 2017-08-01 Bionor Immuno As peptídeos imunogênicos multiméricos e monoméricos
US10342862B2 (en) 2011-01-26 2019-07-09 Glaxosmithkline Biologicals, Sa RSV immunization regimen
LT2707385T (lt) 2011-05-13 2017-12-11 Glaxosmithkline Biologicals Sa Iš anksto sulieti rsv f antigenai
AU2013273482A1 (en) 2012-06-06 2014-12-11 Bionor Immuno As Peptides derived from viral proteins for use as immunogens and dosage reactants
EP3313439A2 (en) 2015-06-26 2018-05-02 Seqirus UK Limited Antigenically matched influenza vaccines
US12128100B2 (en) 2018-11-13 2024-10-29 Variation Biotechnologies Inc. Immunogenic compositions for treatment of Hepatitis B
WO2021160887A1 (en) 2020-02-14 2021-08-19 Immunor As Corona virus vaccine

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0175261B1 (en) * 1984-09-12 1991-12-11 Chiron Corporation Hybrid particle immunogens
NZ227011A (en) * 1987-11-18 1992-03-26 Chiron Corp Non-a, non-b-hepatitis (hepatitis c) antigens, proteins, nucleotide sequences, vaccines and kits
WO1989012641A1 (en) * 1988-06-17 1989-12-28 Genelabs Incorporated Enterically transmitted non-a/non-b hepatitis viral agent
US4912094B1 (en) * 1988-06-29 1994-02-15 Ribi Immunochem Research Inc. Modified lipopolysaccharides and process of preparation
DK0414374T3 (da) * 1989-07-25 1998-03-09 Smithkline Beecham Biolog Hidtil ukendte antigener og fremgangsmåder til fremstilling deraf
JP3156200B2 (ja) * 1989-09-15 2001-04-16 国立予防衛生研究所長 新規のhcv分離株
IL97985A0 (en) * 1990-05-07 1992-06-21 North American Vaccine Inc Improved vaccine compositions
JPH06503821A (ja) * 1990-12-20 1994-04-28 スミスクライン・ビーチャム・バイオロジカルス(ソシエテ・アノニム) B型肝炎表面抗原に基づくワクチン

Also Published As

Publication number Publication date
EP0633784B2 (en) 2001-10-17
CN1072963C (zh) 2001-10-17
JPH07505372A (ja) 1995-06-15
KR950700757A (ko) 1995-02-20
AU6445796A (en) 1996-11-07
JP3470719B2 (ja) 2003-11-25
UA44688C2 (uk) 2002-03-15
NO943571L (no) 1994-11-14
ATE146678T1 (de) 1997-01-15
AU767755B2 (en) 2003-11-20
AU3751693A (en) 1993-11-08
MA22842A1 (fr) 1993-10-01
NO943571D0 (no) 1994-09-26
FI110843B (fi) 2003-04-15
DK0633784T3 (da) 1997-01-20
DE69306940D1 (de) 1997-02-06
AP9300502A0 (en) 1993-04-30
CZ283424B6 (cs) 1998-04-15
IL105161A0 (en) 1993-07-08
GR3022174T3 (en) 1997-03-31
HU9402758D0 (en) 1994-12-28
CA2132833A1 (en) 1993-10-14
SI9300149B (sl) 2003-02-28
KR100270134B1 (ko) 2000-10-16
MY111880A (en) 2001-02-28
NZ249868A (en) 1997-03-24
RU94042386A (ru) 1996-08-20
ES2098029T3 (es) 1997-04-16
SG48375A1 (en) 1998-04-17
SK115294A3 (en) 1995-06-07
AU1000802A (en) 2002-02-21
AU3397499A (en) 1999-08-19
ES2098029T5 (es) 2002-03-16
DE69306940T3 (de) 2002-09-19
SI9300149A (en) 1993-12-31
EP0633784B1 (en) 1996-12-27
SK280160B6 (sk) 1999-09-10
DK0633784T4 (da) 2001-12-31
NO309458B1 (no) 2001-02-05
WO1993019780A1 (en) 1993-10-14
EP0633784A1 (en) 1995-01-18
HU221253B1 (en) 2002-09-28
CZ235594A3 (en) 1995-02-15
DE69306940T2 (de) 1997-06-26
CA2132833C (en) 2007-03-06
AP570A (en) 1996-11-29
IL105161A (en) 1998-08-16
FI944442L (fi) 1994-09-26
HUT69931A (en) 1995-09-28
RU2121849C1 (ru) 1998-11-20
HK1003218A1 (en) 1998-10-16
CN1085805A (zh) 1994-04-27
SA93130573B1 (ar) 2004-08-31

Similar Documents

Publication Publication Date Title
FI944442L (fi) 3-O-deasyloitua monofosforyylilipidiä A sisältäviä maksatulehdusrokotteita
DK0689454T4 (da) Vaccinepræparater indeholdende 3-O-deacyleret monophosphoryl-lipid A
FI943171L (fi) Ureaasipohjainen rokote Helicobacter-infektiota vastaan
DK0512017T3 (da) Vacciner
NO976060D0 (no) Vaksiner mot hepatitt C
NO950483D0 (no) Vaksine mot hepatitt-A
FI933210L (fi) Avirulent vaccin mot rabies
FI934725L (fi) Kombinationsvaccin mot barnsjukdomar med oekad immunogenicitet hos varje vaccinkomponent
IL79740A0 (en) Hepatitis vaccine
ATA238986A (de) Vorsatzelement fuer eine wand
IL94510A0 (en) Influenza vaccine
FI874276L (fi) Vaccin mot hepatitis a.
IL86573A0 (en) Influenza vaccine
IL106609A0 (en) Hepatitis a virus vaccine
GB9006097D0 (en) Vaccines
GB9011358D0 (en) Vaccines

Legal Events

Date Code Title Description
MA Patent expired